Global Radiation-Induced Oral Mucositis (RIOM) Market in Head and Neck Cancer 2021 – Insights, Epidemiology and Forecasts to 2030

0


DUBLIN, December 10, 2021– (BUSINESS WIRE) – Radiation-Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) – Market Insights, Epidemiology, and Market Forecast – 2030 has been added ResearchAndMarkets.com to offer.

This report provides a detailed understanding of radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC), the historical and predicted epidemiology, and radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC.). ) Market trends in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan.

It features Current Treatment Practices, New Drugs, Radiation Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) market share of each therapy, Current and Predicted Radiation Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) market size from 2018 to 2030 , divided into seven major markets. The report also covers the current radiation-induced oral mucositis (RIOM) in Head and Neck Cancer (HNC) treatment practice / algorithm, market drivers, market barriers and unmet medical needs to curate the best opportunities, and assess the underlying potential of the Market.

Radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) epidemiology

The Department of Epidemiology of Radiation-Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) provides insight into the historical and current patient pool of radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) and forecast trends for all seven Majors countries. It helps identify the root causes of current and forecast trends by examining numerous studies and views from key opinion leaders. This part of the report also includes the diagnosed patient pool and their trends along with the assumptions made.

Most important findings

In 2020, the total number of radiation-induced oral mucositis (RIOM) cases in head and neck cancer (HNC) was 129.7K cases in the 7MM, which is expected to increase during the study period i.e. 2018-2030.

Disease epidemiology covered in the report features both historical and predicted radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) epidemiology. [segmented as Total Incident Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC), Total Grade-specific Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC), and Total Treated Cases of Radiation-induced Oral Mucositis (RIOM) in Head & Neck Cancer (HNC)] in 7MM, which includes the United States, EU5 countries (Germany, France, Italy, Spain and the United Kingdom) and Japan from 2018 to 2030.

Radiation-Induced Oral Mucositis (RIOM) in Drug Chapters for Head and Neck Cancer (HNC)

The drug chapter segment of the report on Radiation Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) includes the detailed analysis of Radiation Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) drugs marketed and in late-stage (Phase III and Phase II) pipeline drugs. It also helps the details of radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) clinical trials, the expressive pharmacological effects, agreements and collaborations, approval and patent details, advantages and disadvantages of each contained drug, and the latest Understand information news and press releases.

Most important findings

Radiation Induced Oral Mucositis (RIOM) in Head and Neck Cancer (HNC) market size is expected to change in the 7MM space in the 2018-2030 study period. The radiation-induced oral mucositis (RIOM) therapeutic market in head and neck cancer (HNC) in the seven main markets is expected to grow at a CAGR of 12.2% during the study period (2018-2030). The largest market size for radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) is estimated to be in the United States, followed by Japan.

Scope of the report

  • The report provides a descriptive overview of radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) and explains its causes, signs and symptoms, pathophysiology and currently available therapies.

  • Extensive insights into the epidemiology and treatment of radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) were provided at the 7MM.

  • In addition, a comprehensive review of both current and emerging therapies for radiation-induced oral mucositis (RIOM) in head and neck cancer (HNC) is provided, along with an evaluation of new therapies that are having an impact on the current treatment landscape.

  • A Detailed Review of Radiation Induced Oral Mucositis (RIOM) in the Head and Neck Cancer (HNC) Market; The report includes historical and forecast information covering the reach of drugs in the 7MM.

  • The report provides an advantage in developing business strategies by understanding trends shaping and driving the global Radiation-Induced Oral Mucositis (RIOM) Head and Neck Cancer (HNC) Market.

Mentioned companies

  • AMAG Pharma / SpePharm

  • Camurus

  • Innovation Pharma

  • Enzychem Lifesciences Corporation

  • Galera Therapeutics

  • EpicentRx / Prothex Pharma

  • Soligenix

  • Onxeo / Monopar therapeutics

  • Izun Pharma

  • NeoMedLight

  • MuReva phototherapy (Lumitex)

  • BrainCool

Please visit https://www.researchandmarkets.com/r/qft7h0 for more information on this report

View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005266/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For EST office hours, call 1-917-300-0470
For US / CAN toll free call 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. on


Share.

Comments are closed.